545 related articles for article (PubMed ID: 31512195)
21. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
[TBL] [Abstract][Full Text] [Related]
22. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
Nishino H; Takano S; Yoshitomi H; Suzuki K; Kagawa S; Shimazaki R; Shimizu H; Furukawa K; Miyazaki M; Ohtsuka M
Cancer Med; 2017 Nov; 6(11):2686-2696. PubMed ID: 28960866
[TBL] [Abstract][Full Text] [Related]
23. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells.
Passacantilli I; Panzeri V; Bielli P; Farini D; Pilozzi E; Fave GD; Capurso G; Sette C
Cell Death Dis; 2017 Nov; 8(11):e3168. PubMed ID: 29120411
[TBL] [Abstract][Full Text] [Related]
24. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
Mofid MR; Gheysarzadeh A; Bakhtiyari S
Pancreatology; 2020 Oct; 20(7):1442-1450. PubMed ID: 32830034
[TBL] [Abstract][Full Text] [Related]
26. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
[TBL] [Abstract][Full Text] [Related]
27. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
29. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
31. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma.
Yang J; Dong Z; Ren A; Fu G; Zhang K; Li C; Wang X; Cui H
J Cell Mol Med; 2020 Apr; 24(7):4245-4260. PubMed ID: 32141702
[TBL] [Abstract][Full Text] [Related]
32. CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.
El Hassouni B; Mantini G; Immordino B; Peters GJ; Giovannetti E
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817270
[TBL] [Abstract][Full Text] [Related]
33. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
35. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
[TBL] [Abstract][Full Text] [Related]
36. miR-24-3p Regulates Epithelial-Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression.
Huang W; Lin T; Huang L; Wu J; Hong J; Qiu F; Tian Y; Wang Y
Biochem Genet; 2023 Apr; 61(2):742-761. PubMed ID: 36114946
[TBL] [Abstract][Full Text] [Related]
37. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.
Mizuuchi Y; Aishima S; Ohuchida K; Shindo K; Fujino M; Hattori M; Miyazaki T; Mizumoto K; Tanaka M; Oda Y
Lab Invest; 2015 Feb; 95(2):193-206. PubMed ID: 25418581
[TBL] [Abstract][Full Text] [Related]
38. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
[TBL] [Abstract][Full Text] [Related]
39. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
40. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
